MedTrace Logo

Favipiravir Therapy in Adults With Mild COVID-19

NCT04464408 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 231

Last updated 2021-11-05

No results posted yet for this study

Summary

Favipiravir is a selective and potent inhibitor of influenza viral RNA polymerase. It acts as a purine analogue, which selectively inhibits viral RNA-dependent RNA polymerase (RdRps). It has the characteristic of acting on RNA viruses including Ebola and Coronaviruses especially novel coronavirus (2019-nCoV). The purpose of this study is to evaluate the clinical efficacy and safety of Favipiravir in comparison to placebo in the treatment of mild COVID-19 cases. It is a Multicenter, randomized double-blinded, parallel-group trial.

Conditions

Interventions

DRUG

Favipiravir

1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily

DRUG

Placebo

(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)

Sponsors & Collaborators

  • Ministry of Health, Saudi Arabia

    collaborator OTHER_GOV

  • King Abdullah International Medical Research Center

    lead OTHER

Principal Investigators

  • Mohammad Bosaeed · KAMC-RD, Ministry of National Guard Health Affairs (MNGHA), Saudi Arabia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-23
Primary Completion
2021-08-04
Completion
2021-08-04

Countries

  • Saudi Arabia

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04464408 on ClinicalTrials.gov